Articles from MedMira, Inc.

MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
FDA recognition marks a significant regulatory milestone for MedMira's innovative, instrument-free point-of-care diagnostic technology.
By MedMira, Inc. · Via ACCESS Newswire · November 17, 2026
MedMira Reports Third Quarter Results FY2026
HALIFAX, NS / ACCESS Newswire / June 29, 2026 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2026.
By MedMira, Inc. · Via ACCESS Newswire · June 29, 2026
Articles from MedMira, Inc. | FWNBC